27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
Shares of bluebird bio Inc (NASDAQ:BLUE) — a clinical-stage biopharmaceutical company focused on bringing to market advanced products based on the potential of gene therapy — have been highly volatile, but the company has a "clear path" toward commercialization, according to Evercore ISI.
The Analyst
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!
Evercore ISI's Josh Schimmer on June 19 upgraded bluebird from In-line to Outperform with a price target lifted from $175 to $230.
The analyst downgraded Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) from Outperform to In-Line with an unchanged $300 price target.
Bluebird's March Toward Commercialization
Bluebird's recent updates related to its LentiGlobin investigational gene therapy in patients with sickle cell disease and the separate myeloma CAR-T therapy bb2121 with its partner Celgene Corporation (NASDAQ:CELG) represent an "important positive inflection" for the company, Schimmer said in the upgrade note.
Granted, there are still "existential threats down the road" for bluebird, but the biotech has a clear path toward commercialization, the analyst said.
FREE REPORT: How To Learn Options Trading Fast
In this special report, you will learn the four best strategies for trading options, how to stay safe as a complete beginner, a 411% trade case study, PLUS how to access two new potential winning options trades starting today.Claim Your Free Report Here.
Bluebird likely holds an advantage over most competitor CAR-T updates, as its bb2121 has a first-mover advantage and a robust partner in Celgene, Schimmer said. LentiGlobin also faces competition but is poised to gain regulatory approval and commercialization, he said.
Related Link: Janney Says Bluebird's Therapies Are 'Encouraging,' But Stock Is Fairly Valued
Madrigal: 'Quite A Ride'
Madrigal, a clinical-stage biopharmaceutical company pursuing novel therapeutics that target a specific thyroid hormone receptor, The stock traded below $20 per share in 2017 but has since experienced "quite a ride," as it is near the $300 level amid a recent Bloomberg report the company is looking to sell itself, Schimmer said in a downgrade note.
Anything short of an acquisition or "massive" collaboration with a larger partner will likely fall short of investor expectations, the analyst said. Results from the company's Phase 2 MGL-3196 study were "encouraging," but the company faces "some unknowns" related to the long-term outlook of 3196, Schimmer said.
Madrigal is operating in a growing competitive landscape with a finite period of patent exclusivity, the analyst said.
Madrigal's story could improve, as the Phase 3 trial of 3196 will start in 2019, but 12-15 months are needed for enrollment followed by another year for results to be released, according to Evercore.
Until then, there is no "real incremental reason" to buy Madrigal stock at around $300 per share over compelling alternatives within the mid-cap space, Schimmer said.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.